Notably, effective targeted therapies are based upon specific mutations or amplifications in the primary tumor that are directly related to the tumorigenesis, such as human epidermal growth factor receptor 2 (HER2) amplification in breast cancer and epithelial growth factor receptor (EGFR) mutation in lung cancer (42, 43). This evidence concerns the gene ERBB2 and breast carcinoma.